Literature DB >> 21339490

The neurobiology of sphingosine 1-phosphate signaling and sphingosine 1-phosphate receptor modulators.

Betty Soliven1, Veronique Miron, Jerold Chun.   

Abstract

Sphingosine 1-phosphate receptors (S1PRs) are G protein-coupled receptors expressed by many cell types, including immune and neural cells. These receptors are promising targets for immunomodulatory and possibly neuromodulatory therapies. Fingolimod (FTY720) is a sphingosine analog that, when phosphorylated, becomes a prototypical S1PR modulator. It has recently been approved as the first oral treatment for relapsing forms of multiple sclerosis in some countries. Fingolimod has documented effects on lymphocyte egress, selectively retaining lymphocytes within the lymph nodes. In addition, fingolimod can enter the CNS and can act on S1PRs expressed by most neural lineages. In this article, we discuss recent results supporting the concept that S1PR modulators may exert neuroprotective and regenerative actions in the CNS as well as having anti-inflammatory effects.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21339490     DOI: 10.1212/WNL.0b013e31820d9507

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  39 in total

Review 1.  Regulation of mammalian physiology, development, and disease by the sphingosine 1-phosphate and lysophosphatidic acid receptors.

Authors:  Victoria A Blaho; Timothy Hla
Journal:  Chem Rev       Date:  2011-09-22       Impact factor: 60.622

Review 2.  A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya).

Authors:  Jerold Chun; Volker Brinkmann
Journal:  Discov Med       Date:  2011-09       Impact factor: 2.970

Review 3.  Neuron-astroglial interactions in cell-fate commitment and maturation in the central nervous system.

Authors:  Joice Stipursky; Tânia Cristina Leite de Sampaio E Spohr; Vivian Oliveira Sousa; Flávia Carvalho Alcantara Gomes
Journal:  Neurochem Res       Date:  2012-05-22       Impact factor: 3.996

4.  Fingolimod: Lessons Learned and New Opportunities for Treating Multiple Sclerosis and Other Disorders.

Authors:  Jerold Chun; Yasuyuki Kihara; Deepa Jonnalagadda; Victoria A Blaho
Journal:  Annu Rev Pharmacol Toxicol       Date:  2019-01-06       Impact factor: 13.820

5.  Acute relapse after initiation of Siponimod in a patient with secondary progressive MS.

Authors:  Rehana Hussain; Shirley O'Leary; Fides M Pacheco; Tresa E Zacharias; Paul Litvak; Peter Sguigna; Ellen Marder; Kevin Kia; Karanjit Kooner; Olaf Stüve
Journal:  J Neurol       Date:  2016-02-25       Impact factor: 4.849

6.  A practical process for the preparation of [(32)P]S1P and binding assay for S1P receptor ligands.

Authors:  Adam J Rosenberg; Hui Liu; Zhude Tu
Journal:  Appl Radiat Isot       Date:  2015-04-17       Impact factor: 1.513

7.  Effect of Fingolimod on Neural Stem Cells: A Novel Mechanism and Broadened Application for Neural Repair.

Authors:  Yuan Zhang; Xing Li; Bogoljub Ciric; Cun-Gen Ma; Bruno Gran; Abdolmohamad Rostami; Guang-Xian Zhang
Journal:  Mol Ther       Date:  2016-12-28       Impact factor: 11.454

Review 8.  Lysophospholipid receptor nomenclature review: IUPHAR Review 8.

Authors:  Yasuyuki Kihara; Michael Maceyka; Sarah Spiegel; Jerold Chun
Journal:  Br J Pharmacol       Date:  2014-07-12       Impact factor: 8.739

9.  Dose titration of BAF312 attenuates the initial heart rate reducing effect in healthy subjects.

Authors:  Eric Legangneux; Anne Gardin; Donald Johns
Journal:  Br J Clin Pharmacol       Date:  2013-03       Impact factor: 4.335

10.  Fingolimod reduces hemorrhagic transformation associated with delayed tissue plasminogen activator treatment in a mouse thromboembolic model.

Authors:  Francisco Campos; Tao Qin; José Castillo; Ji Hae Seo; Ken Arai; Eng H Lo; Christian Waeber
Journal:  Stroke       Date:  2013-01-03       Impact factor: 7.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.